Lower-sodium oxybate (LXB) is an oxybate medication approved to treat cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy 7 years of age and older in the United States. LXB was developed as an alternative to sodium oxybate (SXB), because the incidence of cardiovascular comorbidities is higher in patients with narcolepsy and there is an elevated cardiovascular risk associated with high sodium consumption. LXB has a unique formulation of calcium, magnesium, potassium, and sodium ions, containing 92% less sodium than SXB. Whereas the active oxybate moiety is the same for LXB and SXB, their pharmacokinetic profiles are not bioequivalent; therefore, a phase 3 trial in participants with narcolepsy was conducted for LXB. This review summarizes the background on oxybate as a therapeutic agent and its potential mechanism of action on the gamma-aminobutyric acid type B (GABAB) receptor at noradrenergic and dopaminergic neurons, as well as at thalamocortical neurons. The rationale leading to the development of LXB as a lower-sodium alternative to SXB and the key efficacy and safety data supporting its approval for both adult and pediatric patients with narcolepsy are also discussed. LXB was approved in August 2021 in the United States for the treatment of idiopathic hypersomnia in adults. Potential future developments in the field of oxybate medications may include novel formulations and expanded indications for other diseases.

Department of Neurology 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Department of Neurology Albert Einstein College of Medicine Bronx NY USA

Helsinki Sleep Clinic Terveystalo Healthcare and Department of Clinical Neurosciences University of Helsinki Helsinki Finland

Sleep and Wake Disorders Centre Department of Neurology Gui de Chauliac Hospital Montpellier France

Sleep Disorders Center Department of Neurology Cleveland Clinic Cleveland OH USA

University of Montpellier INSERM Institute Neuroscience Montpellier Montpellier France

University of South Carolina School of Medicine Columbia SC USA

Zobrazit více v PubMed

Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. PubMed DOI PMC

Bassetti CLA, Kallweit U, Vignatelli L, et al. European guideline and expert statements on the management of narcolepsy in adults and children. PubMed DOI

Caputo F, Del Re A, Brambilla R, et al. Sodium oxybate in maintaining alcohol abstinence in alcoholic patients according to Lesch typologies: a pilot study. PubMed DOI

Xyrem

Billiard M, Bassetti C, Dauvilliers Y, et al. EFNS guidelines on management of narcolepsy. PubMed DOI

Wang YG, Swick TJ, Carter LP, Thorpy MJ, Benowitz NL. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. PubMed DOI PMC

Xyrem [summary of product characteristics]. Brussels, Belgium: UCB Pharma; 2021.

U.S. Xyrem Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. PubMed

U.S. Xyrem Multicenter Study Group. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. PubMed

U.S. Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. PubMed DOI

Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. PubMed DOI

Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. PubMed DOI

Strunc MJ, Black J, Lillaney P, et al. The Xyrem( PubMed DOI PMC

Carter LP, Pardi D, Gorsline J, Griffiths RR. Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse. PubMed DOI PMC

George J, Majeed W, Mackenzie IS, Macdonald TM, Wei L. Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study. PubMed DOI PMC

Wei L, Mackenzie IS, MacDonald TM, George J. Cardiovascular risk associated with sodium-containing medicines. PubMed DOI

Whelton PK, Appel LJ, Sacco RL, et al. Sodium, blood pressure, and cardiovascular disease: further evidence supporting the American Heart Association sodium reduction recommendations. PubMed DOI

Clinical superiority findings; 2021. Available from: https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/clinical-superiority-findings. Accessed July 9, 2021.

Food and Drug Administration. Voluntary sodium reduction goals: target mean and upper bound concentrations for sodium in commercially processed, packaged, and prepared foods: guidance for industry; 2021. Available from: https://www.fda.gov/media/98264/download. Accessed December 8, 2021.

Chen C, Jenkins J, Zomorodi K, Skowronski R. Pharmacokinetics, bioavailability, and bioequivalence of lower-sodium oxybate in healthy participants in 2 open-label, randomized, crossover studies. PubMed DOI PMC

Bogan RK, Thorpy MJ, Dauvilliers Y, et al. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy. PubMed DOI PMC

Morse AM, Chen C, Wang YG, Skowronski RJ, Plazzi G. Evidence to support dose regimens for lower-sodium oxybate in pediatric patients with narcolepsy: phase 3 clinical data, pharmacokinetic (PK) data, and population PK modeling [oral presentation]. Paper presented at: Biennial Congress of the International Pediatric Sleep Association; February 5–6, 2021; 2021.

Xywav

Kothare SV, Kaleyias J. Pharmacotherapy of narcolepsy: focus on sodium oxybate.

Saytzeff A. [On the reduction of succinyl chloride]. DOI

Gamma-hydroxybutyric acid (GHB) critical review report; 2012. Available from: https://www.who.int/medicines/areas/quality_safety/4.1GHBcritical_review.pdf. Accessed January 19, 2022.

Laborit H. Sodium 4-hydroxybutyrate. PubMed DOI

Bertharion C, Laborit H. [Stereotactic study of the potentials evoked by sodium 4-hydroxybutyrate.

Danon-Boileau H, Lavitry S, Lab P, Levy E, Ruffiot S, Laborit H. [Utilization in psychiatry of gamma-OH]. PubMed

Rinaldi F, Puca FM, Mastrosimone F, Memoli G. [On the use of gamma-hydroxybutyrate of sodium in psychiatric therapy]. PubMed

Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate. PubMed DOI

Guiraud J, Addolorato G, Aubin HJ, et al. Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate: results of a randomised, double-blind, placebo-controlled study. PubMed DOI

Plazzi G, Ruoff C, Lecendreux M, et al. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation. PubMed DOI

Dauvilliers Y, Arnulf I, Foldvary-Schaefer N, et al. Efficacy and safety of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomized withdrawal study. PubMed

Venzi M, Di Giovanni G, Crunelli V. A critical evaluation of the gamma-hydroxybutyrate (GHB) model of absence seizures. PubMed DOI PMC

GHB drug fact sheet; 2020. Available from: https://www.dea.gov/factsheets/ghb-gamma-hydroxybutyric-acid. Accessed April 27, 2021.

Drug scheduling; 2019. Available from: https://www.dea.gov/drug-scheduling. Accessed May 23, 2019.

Fuller DE, Hornfeldt CS, Kelloway JS, Stahl PJ, Anderson TF. The Xyrem risk management program. PubMed DOI

Silber MH, Krahn LE, Olson EJ, Pankratz VS. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. PubMed DOI

Longstreth WT Jr, Ton TG, Koepsell T, Gersuk VH, Hendrickson A, Velde S. Prevalence of narcolepsy in King County, Washington, USA. PubMed DOI PMC

Vignatelli L, Antelmi E, Ceretelli I, et al. Red flags for early referral of people with symptoms suggestive of narcolepsy: a report from a national multidisciplinary panel. PubMed DOI PMC

Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. PubMed DOI

Narcolepsy Type 2.

Narcolepsy Type 1.

Bassetti CLA, Adamantidis A, Burdakov D, et al. Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment. PubMed DOI

Fraigne JJ, Torontali ZA, Snow MB, Peever JH. REM sleep at its core - circuits, neurotransmitters, and pathophysiology. PubMed DOI PMC

Scammell TE. Narcolepsy. PubMed DOI

Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. PubMed DOI

Kornum BR, Knudsen S, Ollila HM, et al. Narcolepsy. PubMed DOI

Pardi D, Black J. gamma-Hydroxybutyrate/sodium oxybate: neurobiology, and impact on sleep and wakefulness. PubMed DOI

Crunelli V, Emri Z, Leresche N. Unravelling the brain targets of gamma-hydroxybutyric acid. PubMed DOI PMC

Roth RH. Striatal dopamine and gamma-hydroxybutyrate. PubMed DOI

Spano PF, Tagliamonte A, Tagliamonte P, Gessa GL. Stimulation of brain dopamine synthesis by gamma-hydroxybutyrate. PubMed DOI

Howard SG, Feigenbaum JJ. Effect of gamma-hydroxybutyrate on central dopamine release in vivo. A microdialysis study in awake and anesthetized animals. PubMed DOI

Aghajanian GK, Roth RH. Gamma-hydroxybutyrate-induced increase in brain dopamine: localization by fluorescence microscopy. PubMed

Hechler V, Gobaille S, Bourguignon JJ, Maitre M. Extracellular events induced by gamma-hydroxybutyrate in striatum: a microdialysis study. PubMed DOI

Roth RH, Walters JR, Aghajanian GK. Effect of impulse flow on the release and synthesis of dopamine in the rat striatum. In: Usdin E, Snyder SH, editors. Frontiers in Catecholamine Research. Proceedings of the Third International Catecholamine Symposium Held at the University of Strasbourg, Strasbourg, France May 20–25, 1973. New York, NY: Pergamon Press Inc.; 1973:567–574.

Szabo ST, Gold MS, Goldberger BA, Blier P. Effects of sustained gamma-hydroxybutyrate treatments on spontaneous and evoked firing activity of locus coeruleus norepinephrine neurons. PubMed DOI

Schmidt-Mutter C, Muller C, Zwiller J, Gobaille S, Maitre M. Gamma-hydroxybutyrate and cocaine administration increases mRNA expression of dopamine D1 and D2 receptors in rat brain. PubMed DOI

Gottesmann C. GABA mechanisms and sleep. PubMed DOI

Scammell TE, Arrigoni E, Lipton JO. Neural circuitry of wakefulness and sleep. PubMed DOI PMC

Wisor JP. Dopamine and wakefulness: pharmacology, genetics, and circuitry. PubMed

Gruner JA, Marcy VR, Lin YG, Bozyczko-Coyne D, Marino MJ, Gasior M. The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents. PubMed DOI PMC

Dauvilliers Y, Tafti M, Landolt HP. Catechol-O-methyltransferase, dopamine, and sleep-wake regulation. PubMed DOI

Burgess CR, Tse G, Gillis L, Peever JH. Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy. PubMed DOI PMC

Roth RH, Doherty JD, Walters JR. Gamma-hydroxybutyrate: a role in the regulation of central dopaminergic neurons? PubMed DOI

Engberg G, Nissbrandt H. gamma-Hydroxybutyric acid (GHBA) induces pacemaker activity and inhibition of substantia nigra dopamine neurons by activating GABAB-receptors. PubMed DOI

Brown RE, Basheer R, McKenna JT, Strecker RE, McCarley RW. Control of sleep and wakefulness. PubMed DOI PMC

Schmidt C, Leibiger J, Fendt M. The norepinephrine reuptake inhibitor reboxetine is more potent in treating murine narcoleptic episodes than the serotonin reuptake inhibitor escitalopram. PubMed DOI

Barateau L, Jaussent I, Roeser J, Ciardiello C, Kilduff TS, Dauvilliers Y. Cerebrospinal fluid monoamine levels in central disorders of hypersomnolence. PubMed DOI PMC

Shefner SA, Osmanovic SS. GABAA and GABAB receptors and the ionic mechanisms mediating their effects on locus coeruleus neurons. PubMed

Williams SR, Turner JP, Crunelli V. Gamma-hydroxybutyrate promotes oscillatory activity of rat and cat thalamocortical neurons by a tonic GABAB, receptor-mediated hyperpolarization. PubMed DOI

Gervasi N, Monnier Z, Vincent P, et al. Pathway-specific action of gamma-hydroxybutyric acid in sensory thalamus and its relevance to absence seizures. PubMed DOI PMC

Roth T, Dauvilliers Y, Mignot E, et al. Disrupted nighttime sleep in narcolepsy. PubMed DOI PMC

Maski K, Mignot E, Plazzi G, Dauvilliers Y. Disrupted nighttime sleep and sleep instability in narcolepsy. PubMed DOI PMC

Ohayon MM. Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population. PubMed DOI

Cohen A, Mandrekar J, St Louis EK, Silber MH, Kotagal S. Comorbidities in a community sample of narcolepsy. PubMed DOI PMC

Black J, Reaven NL, Funk SE, et al. Medical comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study. PubMed DOI

Jennum PJ, Plazzi G, Silvani A, Surkin LA, Dauvilliers Y. Cardiovascular disorders in narcolepsy: review of associations and determinants. PubMed DOI

Dahmen N, Bierbrauer J, Kasten M. Increased prevalence of obesity in narcoleptic patients and relatives. PubMed DOI

Bosco A, Lopez R, Barateau L, et al. Effect of psychostimulants on blood pressure profile and endothelial function in narcolepsy. PubMed DOI

Grimaldi D, Calandra-Buonaura G, Provini F, et al. Abnormal sleep-cardiovascular system interaction in narcolepsy with cataplexy: effects of hypocretin deficiency in humans. PubMed DOI PMC

Vandi S, Rodolfi S, Pizza F, et al. Cardiovascular autonomic dysfunction, altered sleep architecture, and muscle overactivity during nocturnal sleep in pediatric patients with narcolepsy type 1. PubMed DOI

Ohkubo T, Hozawa A, Yamaguchi J, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. PubMed DOI

Dauvilliers Y, Jaussent I, Krams B, et al. Non-dipping blood pressure profile in narcolepsy with cataplexy. PubMed DOI PMC

National Academies of Sciences Engineering and Medicine. PubMed

Junnarkar G, Allphin C, Profant J, et al. Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia. PubMed DOI

Wang Q, Lin T, Allphin C, van Osdol WW, Bolger MB, Chen C. Physiologically based pharmacokinetic modeling of oxybate: the role of counter-ions in gastrointestinal absorption of oxybate [poster]. Paper presented at: Annual AAPS PharmSci 360; October 26–November 5, 2020; 2020.

Bogan RK, Foldvary-Schaefer N, Skowronski R, Chen A, Thorpy MJ. Timing and duration of treatment-emergent adverse events in a clinical trial of lower-sodium oxybate in participants with narcolepsy with cataplexy [poster 486]. Paper presented at: Annual Meeting of the Associated Professional Sleep Societies; June 10–13, 2021; 2021.

Husain AM, Bujanover S, Ryan R, Scheckner B, Black J, Profant J. Incidence and duration of common, early-onset adverse events occurring during 2 randomized, placebo-controlled, phase 3 studies of sodium oxybate in participants with narcolepsy. PubMed DOI PMC

Gardener H, Rundek T, Wright CB, Elkind MS, Sacco RL. Dietary sodium and risk of stroke in the Northern Manhattan study. PubMed DOI PMC

Strazzullo P, D’Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. PubMed DOI PMC

Plazzi G, Ruoff C, Hassan F, et al. Clinical and patient global impression in a study of sodium oxybate in children and adolescents with narcolepsy with cataplexy [abstract P515].

Borgen LA, Okerholm RA, Lai A, Scharf MB. The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients. PubMed DOI

Chen C, Rosen CL, Ruoff C, et al. Population and noncompartmental pharmacokinetics of sodium oxybate support weight-based dosing in children and adolescents with narcolepsy with cataplexy. PubMed DOI PMC

Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. PubMed DOI PMC

Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. PubMed DOI PMC

Jazz Pharmaceuticals announces U.S. FDA approval of Xywav

Dauvilliers Y, Evangelista E, Barateau L, et al. Measurement of symptoms in idiopathic hypersomnia: the Idiopathic Hypersomnia Severity Scale. PubMed DOI

Avadel Pharmaceuticals announces ongoing FDA review of NDA for FT218 for patients with narcolepsy [press release]; 2021. Available from: https://www.globenewswire.com/news-release/2021/10/15/2315210/0/en/Avadel-Pharmaceuticals-Announces-Ongoing-FDA-Review-of-NDA-for-FT218-for-Patients-with-Narcolepsy.html. Accessed November 5, 2021.

Kushida CA, Shapiro CM, Roth T, et al. Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy. PubMed DOI PMC

Xiang W, Xiang J-N, Canafax D. Clinical pharmacokinetics of XW10172 for once-nightly therapy in patients with narcolepsy or sleep disorders in patients with neurodegenerative diseases [poster]. Paper presented at: Annual Meeting of the Associated Professional Sleep Societies; June 10–13, 2021; 2021.